DNA甲基转移酶1和叉头蛋白转录因子O亚型3a在结肠癌中的表达关系研究

doi:10.3760/cma.j.cn371439-20201119-00145

摘要/Abstract

摘要： 目的通过检测DNA甲基转移酶1(DNMT1)和叉头蛋白转录因子O亚型(FOXO)3a在结肠癌患者血清中的水平,分析两者在结肠癌中的关系以及联合检测预测结肠癌发生的诊断效能。方法选取2019年9月至2020年9月西安国际医学中心医院确诊并收治的结肠癌患者105例作为结肠癌组,65例同期经活检确诊的结肠息肉患者作为对照组。采用实时荧光定量PCR检测患者血清中DNMT1、FOXO3a水平;Pearson相关分析结肠癌患者血清中DNMT1、FOXO3a的相关性;采用受试者工作特征曲线对DNMT1、FOXO3a水平在结肠癌中的诊断价值进行评估。结果对照组与结肠癌组患者血清中DNMT1水平分别为0.93±0.28和1.34±0.35,与对照组相比,结肠癌组患者中DNMT1水平显著升高,差异具有统计学意义(t=7.990,P<0.001);两组患者血清中FOXO3a水平分别为1.04±0.39和0.69±0.18,与对照组相比,结肠癌组患者中FOXO3a水平降低,差异具有统计学意义(t=7.940,P<0.001)。DNMT1和FOXO3a的水平在结肠癌患者血清中呈负相关(r=-0.687,P<0.001)。DNMT1预测结肠癌发生的曲线下面积(AUC)为0.843,敏感性为71.40%,特异性为90.80%;FOXO3a预测结肠癌发生的AUC为0.812,敏感性为88.60%,特异性为67.70%;二者联合预测结肠癌发生的AUC为0.859,敏感性为89.50%,特异性为92.30%;与FOXO3a单独检测相比,二者联合检测对结肠癌的预测价值更高(Z=1.982,P=0.047)。结论结肠癌患者血清中DNMT1水平升高,FOXO3a水平则降低,二者在结肠癌患者血清中呈负相关,二者联合检测能够有效提高结肠癌的诊断价值。

关键词: 结肠肿瘤, DNA甲基转移酶1, 叉头蛋白转录因子O亚型3a

Abstract: Objective To analyze the relationship between DNA methyltransferase 1 (DNMT1) and forkhead box O3a (FOXO3a) in colon cancer and the diagnostic efficacy of combined detection in predicting the occurrence of colon cancer by detecting the levels of DNMT1 and FOXO3a in serum of colon cancer patients. Methods A total of 105 patients with colon cancer diagnosed and treated in Xi'an International Medical Center Hospital from September 2019 to September 2020 were selected as the colon cancer group, and 65 patients with colon polyps diagnosed by biopsy during the same period were selected as control group. The levels of DNMT1 and FOXO3a in serum of patients were detected by real-time fluorescence quantitative PCR. Pearson correlation coefficient method was used to analyze the correlation between the levels of DNMT1 and FOXO3a in serum of patients with colon cancer. Subject operating characteristic curve was used to evaluate the diagnostic values of DNMT1 and FOXO3a levels in colon cancer. Results The serum levels of DNMT1 in the control group and colon cancer group were 0.93±0.28 and 1.34±0.35, compared with the control group, the level of DNMT1 in the colon cancer group was significantly higher, with a statistically significant difference (t=7.990, P<0.001). The serum levels of FOXO3a were 1.04±0.39 and 0.69±0.18, compared with the control group, the level of FOXO3a in the colon cancer group was significantly lower, with a statistically significant difference (t=7.940, P=0.001). The serum levels of DNMT1 and FOXO3a in patients with colon cancer were negatively correlated (r=-0.687, P<0.001). The area under the curve (AUC) of DNMT1 predicting colon cancer was 0.843, the sensitivity was 71.40%, and the specificity was 90.80%. The AUC of FOXO3a predicting colon cancer was 0.812, the sensitivity was 88.60%, and the specificity was 67.70%. The AUC of the two combined predicting colon cancer was 0.859, the sensitivity was 89.50%, and the specificity was 92.30%. Compared with FOXO3a single detection, the predictive value of combined detection of DNMT1 and FOXO3a were higher (Z=1.982, P=0.047). Conclusion The level of DNMT1 in the serum of patients with colon cancer is increased, while the level of FOXO3a is decreased. There is a negative correlation between them in the serum of patients with colon cancer. The combined detection of the DNMT1 and FOXO3a can effectively improve the diagnostic value of colon cancer.

Key words: Colon neoplasms, DNA methyltransferase 1, Forkhead box O3a

刘瑾, 陈翔, 马群, 童东东. DNA甲基转移酶1和叉头蛋白转录因子O亚型3a在结肠癌中的表达关系研究[J]. 国际肿瘤学杂志, 2021, 48(12): 735-738.

Liu Jin, Chen Xiang, Ma Qun, Tong Dongdong. Study on expression relationship of DNA methyltransferase 1 and forkhead box O3a in colon cancer[J]. Journal of International Oncology, 2021, 48(12): 735-738.

图/表 3

参考文献 14

[1]	赵高传, 陈卿奇, 庞莉 , 等. miR-205及miR-221在结肠癌患者血清中的水平及其临床意义[J]. 国际肿瘤学杂志, 2019,46(9):526-530. DOI: 10.3760/cma.j.issn.1673-422X.2019.09.003.
[2]	江慧洪, 林谋斌 . DNA甲基化在结直肠癌早期诊断中的研究进展[J]. 同济大学学报(医学版), 2019,40(5):639-643. DOI: 10.16118/j.1008-0392.2019.05.020.
[3]	高晓斌, 武雪亮, 赵轶峰 , 等. DNMT1和DNMT3a在结直肠癌中的表达、临床意义及相关性研究[J]. 中国医药导报, 2020,17(1):17-20, 37.
[4]	马偲程, 武丽萍, 赵华文 , 等. 结直肠癌相关的原癌基因和抑癌基因研究现状及进展[J]. 河北医药, 2019,41(14):2210-2215. DOI: 10.3969/j.issn.1002-7386.2019.14.033.
[5]	Liu H, Song Y, Qiu H, et al. Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis[J]. Cell Death Differ, 2020,27(3):966-983. DOI: 10.1038/s41418-019-0389-3.
[6]	De Rosa M, Pace U, Rega D, et al. Genetics, diagnosis and management of colorectal cancer (review)[J]. Oncol Rep, 2015,34(3):1087-1096. DOI: 10.3892/or.2015.4108.
[7]	Li J, Su X, Dai L, et al. Temporal DNA methylation pattern and targeted therapy in colitis-associated cancer[J]. Carcinogenesis, 2020,41(2):235-244. DOI: 10.1093/carcin/bgz199.
[8]	韩竞男, 鲁昊骋, 梁静 . DNA甲基化与癌症[J]. 中国生物化学与分子生物学报, 2012,28(2):108-114.
[9]	高晓斌, 武雪亮, 赵轶峰 , 等. 结直肠癌组织中DNA甲基转移酶-1和钠氢交换子调节因子1的表达、临床意义及相关性[J]. 中国医药导报, 2020,17(2):20-24.
[10]	王居峰, 刘莺, 刘文静 , 等. 沉默Dnmt1基因对结肠癌细胞株HT-29细胞增殖及细胞周期的影响[J]. 广东医学, 2010,31(14):1798-1800.
[11]	Dong Z, Yang J, Li L, et al. FOXO3a SIRT6 axis suppresses aerobic glycolysis in melanoma[J]. Int J Oncol, 2020,56(3):728-742. DOI: 10.3892/ijo.2020.4964.
[12]	Yang S, Li X, Guan W, et al. NVP-BKM120 inhibits colon cancer growth via FoxO3a-dependent PUMA induction[J]. Oncotarget, 2017,8(47):83052-83062. DOI: 10.18632/oncotarget.20943.
[13]	Ju H, Tan JY, Cao B, et al. Effects of miR-223 on colorectal cancer cell proliferation and apoptosis through regulating FoxO3a/BIM[J]. Eur Rev Med Pharmacol Sci, 2018,22(12):3771-3778. DOI: 10.26355/eurrev_201806_15259.
[14]	Liu Y, Ao X, Ding W, et al. Critical role of FOXO3a in carcinoge-nesis[J]. Mol Cancer, 2018,17(1):104. DOI: 10.1186/s12943-018-0856-3.

组别	性别 (男/女)	年龄 (岁)	体质量指数 (kg/m²)		高血压史 (无/有)
对照组 (n=65)	33/32	47.34±11.81	24.69±4.32	30/35	46/19
结肠癌组 (n=105)	54/51	48.56±11.55	24.98±3.61	50/55	70/35
χ²/t值	0.007	0.664	0.472	0.035	0.312
P值	0.933	0.508	0.638	0.852	0.577

[1]	褚雪镭, 毛昀, 薛鹏, 李林潞, 陈美池, 袁淳晟, 秦晓艳, 朱世杰. 化疗剂量强度对晚期结肠癌患者近期疗效的影响：基于真实世界数据研究[J]. 国际肿瘤学杂志, 2022, 49(7): 408-415.
[2]	来比江·吾斯曼, 曹博威, 张文斌, 高华. 外源性AGR2对结肠癌细胞增殖及侵袭能力的影响[J]. 国际肿瘤学杂志, 2022, 49(2): 73-78.
[3]	李倩倩, 朱晓娣, 赵荣兰, 彭效祥. P2X7受体在结肠癌进展中的作用[J]. 国际肿瘤学杂志, 2021, 48(4): 250-253.
[4]	刘新德, 乔雷, 黄哲, 李云泽, 冯勇. 结肠癌术中使用雷替曲塞腹腔灌注化疗的近期疗效及安全性分析[J]. 国际肿瘤学杂志, 2020, 47(8): 501-504.
[5]	周慧萍, 李宇华, 王宇晖, 苏义龙, 杨营营, 徐笑天, 段小群. 常见植物药对结肠癌的防治作用及其作用机制[J]. 国际肿瘤学杂志, 2020, 47(1): 51-55.
[6]	赵高传, 陈卿奇, 庞莉, 程正, 麦芳奇. miR-205及miR-221在结肠癌患者血清中的水平及其临床意义[J]. 国际肿瘤学杂志, 2019, 46(9): 526-530.
[7]	袁扬军, 卢大松, 邓柄取. CIAPIN1蛋白在结肠癌中的表达及其与肿瘤病理学特征的关系[J]. 国际肿瘤学杂志, 2018, 45(8): 483-486.
[8]	黄江, 张生军, 白利杰, 常琦. 结肠癌根治术患者围手术期血清癌胚抗原水平下降与患者预后的关系[J]. 国际肿瘤学杂志, 2017, 44(8): 662-667.
[9]	黄虞，杜冀晖，龚慧，王秀，王磊，李一凡. miR-92a调控KLF4表达影响结肠癌细胞增殖的机制研究[J]. 国际肿瘤学杂志, 2017, 44(11): 812-818.
[10]	万丽娟，陈明卫. 胰岛素抵抗相关因子与结肠癌干细胞的关系[J]. 国际肿瘤学杂志, 2017, 44(10): 790-793.
[11]	甘亚平, 郭晓花, 张君彧, 许晴晴, 吴疆, 王任勇, 邱敏, 蒋汝刚, 刘复兴, 宁志丰. 结肠癌COLO耐药株的构建及其与肿瘤干细胞的关系[J]. 国际肿瘤学杂志, 2016, 43(8): 646-650.
[12]	王建勋，曾甜，张鹏，王治刚，雷海录. NDRG2基因对结肠癌细胞SW620增殖和侵袭力的影响[J]. 国际肿瘤学杂志, 2016, 43(6): 401-404.
[13]	艾晓晴,贾喜花,王晓博,郑淑君,赵霞,张丙信. UHRF1和P53在结肠癌中的表达及临床意义[J]. 国际肿瘤学杂志, 2016, 43(5): 346-349.
[14]	郭宏艳,何利珍,张云霏,张虹,金惠琴,安文文. 结肠癌转移相关基因1及其在肿瘤中的作用[J]. 国际肿瘤学杂志, 2016, 43(1): 32-35.
[15]	赵霞,张丙信,郑淑君,李林,郭建美,马旭东,贾喜花. Apaf-1和AEG-1在结肠癌中的表达及意义[J]. 国际肿瘤学杂志, 2015, 42(7): 508-511.